Rapid onset of chronic urticaria after Moderna COVID-19 booster vaccine

Introduction

The mRNA-based vaccines Spikevax from Moderna (hereafter referred to as Moderna) and Comirnaty from Pfizer-BioNTech (hereafter Pfizer) are the most widely distributed vaccines in Switzerland[1]. The immunization protocol consists of a primary series of two injections 3 to 4 weeks apart and a booster dose 4-6 months later. The booster was approved end of November 2021 by the Swiss regulatory agency (Swissmedic) for the ≥18-year-old population. Since then, we have observed a substantial number of chronic spontaneous urticaria (CSU) rapidly after the booster dose [2, 3]. CSU is defined as recurrent wheals, angioedema, or both for a duration of >6 weeks, frequently associated with a substantial impact on the health-related quality of life [4].

Methods

As a collaborative effort with local allergists, we started an online observational study to better characterize individuals with newly diagnosed CSU possibly related to COVID-19 vaccines in the Canton of Vaud (CSU-VD). Among the 97 first patients, 80 accepted to participate in an online survey. In parallel, we reviewed all cases of CSU related to COVID-19 vaccination reported to Swissmedic (CSU-CH, n=782) (data kindly shared respecting data protection by I. Scholz, Pharmacovigilance Unit). We compared these data to the general population immunized with a booster in the Canton de Vaud (hereafter referred to as VD-booster, n=298,813) and in Switzerland (hereafter referred to as Booster CH, n=3,278,808). The “Commission cantonale (Prof. Pierre-André Michaud) d’éthique de la recherche sur l’être humain” CER-VD (BASEC 2021-00735, Lausanne, Switzerland, https://www.cer-vd.ch/) approved the study.

Results

In 90% (CSU-VD) and 81% (CSU-CH) of the cases, CSU started after the booster. The median time between the vaccination and CSU onset was ten days. Strikingly, 9 out of 10 CSU cases were associated to Moderna vaccine (Table 1). At data collection, 31% patients reported a diagnosis of COVID infection. In those individuals, the median time between the vaccination and CSU onset was 51 days. The overall incidence rate of CSU after a COVID-19 booster per 100,000 persons immunized with a booster was similar in Vaud (24) and Switzerland (19, Table 2). Compared to Pfizer, the relative risk of developing CSU after Moderna was 21 (95% CI 6.5 - 66) and 16 (11 – 24) respectively (Table 2).

Discussion

Our results suggest an association between the booster dose, the Moderna vaccine, and the new onset of CSU, although this adverse event remains rarely reported. A confounding association with the Omicron variant wave is possible but only 31% reported a confirmed infection in CSU-VD. As a potential contributing mechanism warranting further investigations, the Moderna vaccine was significantly more associated with positive skin and basophil activation tests against either of the two mRNA-based vaccines[5].

Overall, these data should not discourage patients from being vaccinated, as this vaccination campaign has been instrumental in reducing COVID-19 burden and preventing millions of deaths[6]. However, urgent guidelines defining the eligibility/dosing for upcoming mRNA-based boosters are needed for patients with systemic urticaria after a mRNA-based COVID-19 vaccine.